Moore Capital Management’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Moore Capital Management’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,000	Closed	-$2.67K	–	629
2022 Q4	$2.67K	Hold	150,000	–	–	﹤0.01%	511
2022 Q3	$11K	Hold	150,000	–	–	﹤0.01%	566
2022 Q2	$12K	Hold	150,000	–	–	﹤0.01%	626
2022 Q1	$30K	Hold	150,000	–	–	﹤0.01%	679
2021 Q4	$81K	Hold	150,000	–	–	﹤0.01%	641
2021 Q3	$90K	Hold	150,000	–	–	﹤0.01%	704
2021 Q2	$114K	Buy	+150,000	New	+$91.1K	﹤0.01%	733

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Moore Capital Management's IBER.WS Position: Q1 2023 in Review

Moore Capital Management sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 150,000 shares — an estimated $2.67K sold.

Moore Capital Management first reported a position in IBER.WS in Q2 2021 and held it in 7 quarters. The position peaked at $114K in Q2 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Moore Capital Management reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Moore Capital Management sold 150,000 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $2.67K.
Moore Capital Management first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 7 quarters.
Moore Capital Management's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $114K in Q2 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.